Michelson Medical Research Foundation Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco Senior Loan ETF
BKLN
|
+$10.6M |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$7.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Real Estate ETF
VNQ
|
+$18.7M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$6.3M |
| 3 |
iShares S&P 500 Value ETF
IVE
|
+$6.22M |
| 4 |
HDV
iShares Core High Dividend ETF
HDV
|
+$5.96M |
| 5 |
ERF
Enerplus Corporation
ERF
|
+$3.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 14.6% |
| 2 | Energy | 4.78% |
| 3 | Industrials | 0.41% |
| 4 | Financials | 0.41% |
Similar funds
Michelson Medical Research Foundation's Q1 2023 Portfolio in Review
As of Q1 2023, Michelson Medical Research Foundation held 31 positions worth $128M, down 17% from $154M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Michelson Medical Research Foundation withdrew a net $28.9M in Q1 2023, closing 10 positions and reducing 3 holdings. Its most notable exit was Vanguard Real Estate ETF, an estimated $18.7M position sold in full.
By sector, the portfolio is most concentrated in Real Estate at 15% of assets, up from 12% a quarter earlier, followed by Energy and Industrials.
Against the trend, Michelson Medical Research Foundation added an estimated $10.6M to Invesco Senior Loan ETF.
- Michelson Medical Research Foundation added most to Invesco Senior Loan ETF in Q1 2023, an estimated $10.6M increase.
- Michelson Medical Research Foundation's biggest Q1 2023 reduction was iShares Core S&P 500 ETF, cutting an estimated $6.3M.
- Michelson Medical Research Foundation fully exited Vanguard Real Estate ETF in Q1 2023, selling an estimated $18.7M.
- Michelson Medical Research Foundation's ten largest holdings make up 81% of its $128M portfolio in Q1 2023.
- Michelson Medical Research Foundation opened 0 new positions and closed 10 in Q1 2023.
- Michelson Medical Research Foundation's portfolio value fell 17% quarter-over-quarter to $128M.
Based on Michelson Medical Research Foundation's 13F filing for Q1 2023, filed 15 May 2023.